Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of T2DM, is a 39-amino acid linear peptide that is comparable in size to the related hormones GIP and GLP-1 [147]. Here, GCG is linked to type 2 diabetes mellitus.